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Abstract
Background: Neurodegenerative diseases are characterized by both mitochondrial dysfunction and activation of
microglia, the macrophages of the brain. Here, we investigate the effects of mitochondrial dysfunction on the
activation profile of microglial cells.
Methods: We incubated primary mouse microglia with the mitochondrial toxins 3-nitropropionic acid (3-NP) or
rotenone. These mitochondrial toxins are known to induce neurodegeneration in humans and in experimental
animals. We characterized lipopolysaccharide- (LPS-) induced microglial activation and the alternative, interleukin-4-
(IL-4-) induced microglial activation in these mitochondrial toxin-treated microglial cells.
Results: We found that, while mitochondrial toxins did not affect LPS-induced activation, as measured by release
of tumor necrosis factor a (TNF-a), interleukin-6 (IL-6) and interleukin-1b (IL-1b), they did inhibit part of the IL-4-
induced alternative activation, as measured by arginase activity and expression, induction of insulin-like growth
factor 1 (IGF-1) and the counteraction of the LPS induced cytokine release.
Conclusions: Mitochondrial dysfunction in microglial cells inhibits part of the IL-4-induced alternative response.
Because this alternative activation is considered to be associated with wound healing and an attenuation of
inflammation, mitochondrial dysfunction in microglial cells might contribute to the detrimental effects of
neuroinflammation seen in neurodegenerative diseases.
Background
Activation of microglial cells, the macrophages of the
brain, is a common and early hallmark of neurodegen-
erative diseases and contributes directly to neuronal
pathology in virtually all CNS diseases [1]. Activated
microglia release a combination of bioactive agents
including interleukin-6 (IL-6), tumor necrosis factor
alpha (TNFa), and insulin-like growth factor 1 (IGF-1).
These bioactive agents have both protective and detri-
mental consequences for the surrounding brain tissue
[2,3]. In most neurodegenerative diseases, levels of pro-
inflammatory cytokines such as TNFa increase, suggest-
ing that a pro-inflammatory activation of microglia, as
also seen with lipopolysaccharide (LPS) stimulation, out-
weighs the protective effects of microglia in these dis-
eases. In contrast to pro-inflammatory activation,
alternative activation is involved in wound healing and
an attenuation of inflammation associated with protec-
tive effects. Alternative activation is induced by the type
2 helper T cell cytokine IL-4, which is produced in the
CNS and appears to be a critical regulator of neuroin-
flammation [4]. This alternative activation of microglia
is characterized by an increase in arginase activity [5].
The activation of microglia also depends on intrinsic
factors. In the SOD1 transgenic mouse model of amyo-
trophic lateral sclerosis (ALS) the exclusion of mutant
SOD1 expression in microglial cells is associated with
decreased inflammation and an extension of life span
[6]. Expression of mutant SOD1 by microglial cells
therefore increases the detrimental effects of these cells.
In fact, microglial cells constitutively express not only
SOD1 but also other proteins that harbor neurodegen-
eration-causing mutations, e.g huntingtin and alpha-
synuclein, and this might also modulate microglial
activation [6-11].
Another hallmark of neurodegenerative diseases are
mitochondrial dysfunctions [12]. Neurodegenerative
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been linked to mitochondrial dysfunction [13], and an
impairment of mitochondrial activity has been observed
in cells and tissues isolated from patients with neurode-
generative diseases. Furthermore, toxins that inhibit the
mitochondrial electron transport chain induce neurode-
generative diseases in humans and animals. For instance,
inhibition of complex I (NADH dehydrogenase) with
rotenone induces a Parkinson disease-like phenotype in
animals with corresponding degeneration of dopaminer-
gic neurons in the substantia nigra of the brain stem.
Inhibition of complex II (succinate dehydrogenase) with
3-nitropropionic acid (3-NP) induces a Huntington dis-
ease-like phenotype in animals with corresponding
degeneration of medium spiny neurons in the striatum
[14]. In the 3-NP-induced neuronal degeneration model,
and in aged mice, activated microglial cells show signs
of mitochondrial dysfunction [15,16]. It is therefore
likely that the molecular pathways activated by neurode-
generative disease-causing mutations or toxins that lead
to mitochondrial dysfunction are also present in micro-
glial cells. Here we hypothesize that mitochondrial dys-
function will change the immunological profile of
microglia. To test our hypothesis we inhibited mito-
chondrial complexes of the electron transport chain of
primary mouse microglial cells and investigated the
inflammatory responses of these cells.
Methods
Cell culture
Mouse microglial cells in primary cultures were pre-
pared as described previously [17]. Briefly, 1-5 day old
C57Bl/6 mice were decapitated according to the guide-
lines of the animal research center of Ulm University,
Ulm, Germany. Meninges were removed from the
brains. Neopallia were dissected and enzymatically (1%
trypsin, Invitrogen, 0.05% DNAse, Worthington, 2 min)
and mechanically dissociated. The resulting cells were
centrifuged (200 × g, 10 min), suspended in culture
medium (DMEM, Invitrogen) supplemented with peni-
cillin (100 U/ml), streptomycin (100 μg/ml) (Invitrogen)
and heat-inactivated fetal bovine serum (10% FBS,
PAA); and plated into 75-cm
2 flasks (BD Falcon) pre-
coated with 1 μg/ml poly-L-Ornithin (Sigma). Cells
from the neopallia of two brains were plated into 10 ml
per flask. After three days, adherent cells were washed
three times with DPBS (Invitrogen) and incubated with
serum-supplemented culture media. After 7-14 days in
culture, floating and loosely attached microglial cells
were manually shaken off, centrifuged (200 × g, 10 min)
and seeded into 96-well plates or 6-well plates (PRI-
MARIA, BD Falkon) at a density of 4 × 10
4 or 6 × 10
5
cells/well respectively or onto coverslips (15 × 10
4 cells/
coverslip) in DMEM without serum (DMEM,
Invitrogen) supplemented with penicillin (100 U/ml),
streptomycin (100 μg/ml) (Invitrogen) and Glutamax
(Invitrogen). Cells in the flasks were reincubated with
serum-supplemented media after the shake-off. Repopu-
lating microglial cells were removed every week for a
total of 4 weeks until fewer microglial cells were
observed. For astrocyte cultures, attached cells in the
flasks were rinsed once with DPBS, detached (0.05% tryp-
sin, 0,5 mM EDTA) and centrifuged (200 × g, 10 min).
Cells were plated onto coverslips (1.5 × 10
4 cells/cover-
slip) in DMEM with 5% FBS and supplemented with
penicillin, streptomycin and Glutamax. Coverslips were
pre-coated with 1 μg/ml poly-L-ornithine.
Immunocytochemistry
For immunocytochemical characterization of mouse
microglia in culture, we used microglial cells 24-48 h
after seeding them on polyornithin coated glass cover
slips. Astrocytes on cover slips were used 48-72 h after
seeding them. Cells were rinsed with PBS, fixed in 4%
paraformaldehyde for 10 min, and rinsed three times
with PBS. Cells were permeabilized with Triton-X100
(0.1%) for 5 min and incubated overnight with primary
antibodies at 4°C in the present of BSA (1%). We used
rat-anti-mouse CD11b at 1:50 (Serotec, MCA74) to
label microglia and rabbit-anti-GFAP at 1:200 (Abcam
ab7779) to label astrocytes. Bound primary antibodies
were detected with Alexa Fluor 568-conjugated goat-
anti-rat IgG (CD11b) at 1:200 or Alexa Fluor 488-conju-
gated goat-anti-rabbit IgG (GFAP) at 1:200. Secondary
antibodies were incubated for 1 h at room temperature.
Stained cells were rinsed with PBS and mounted on
slides with Vectashield with DAPI. Labeling was visua-
lized with an Axiovert 135 microscope. Photographs
were taken with an Axiocam Color digital camera. To
determine the actual quantity of microglial cells in our
microglial culture, we carried out three independent
immunocytochemical characterizations of these cultures,
made three digital images (20× magnification) of ran-
dom areas of each immunostaining, and manually
counted cell nuclei that were stained by DAPI to deter-
mine the total cell number present in the selected area.
In the same area, we also manually counted cells that
were stained by anti-CD11b and anti-GFAP.
Treatment of cells
Microglial cells in 96-well plates were stimulated with
different doses of rotenone (Sigma) or 3-nitropropionic
acid (3-NP) (Sigma) in DMEM without serum for the
indicated times. Rotenone was first dissolved in DMSO
at a concentration of 1 mM. 3-NP was first dissolved in
DPBS at a concentration of 50 mM and the pH was
adjusted to 7.2. From these solutions further dilutions
were made in DMEM without serum. Microglial cells
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1 μg/ml LPS (Sigma).
LDH and WST-1 assays
The LDH assay and WST-1 assay were performed as
described in the manual for the LDH-Cytotoxicity Assay
Kit (Bio Vision) and the WST-1 Assay Kit (Quick Cell
Proliferation Assay Kit; BioVision). For a positive cell
death control, microglia were treated with 1% Triton-
X100 (Sigma) for 30 min.
Arginase activity assay
To measure the arginase activity of microglial cells we
used a modified spectrophotometric assay of arginase as
described by Han and Viola [18]. Briefly we prepared a
15 mM thioarginine (Cayman) solution and a 1 mM
DTNB (Cayman) solution in PBS. We incubated micro-
glial cells in 96-well plates with 0.9 mM thioarginine
and 0.1 mM DTNB in DMEM without serum for a few
hours and measured the absorbance at 412 nm. We
measured an increase in product formation over time in
wells containing microglia in contrast to cell-free wells
that did not show a product formation. The product for-
mation in untreated microglial cells (basal) was set to
100% for our calculations.
ELISAS for IL-6, TNF- a, IL-1 b and IGF-1
The amount of IL-6, TNF-a,I L - 1b and IGF-1 was
determined with specific ELISAs (IL-6, TNF-a and IL-
1b: BioLegend, IGF-1, R&D Systems) as described in the
manuals. After incubation with the toxins, IL-4 and/or
LPS for the indicated times supernatant was used for
the corresponding ELISAs. For the quantification of IL-
1 b microglial cells were stimulated with 3 mM ATP
(Sigma) for 30 min before the collection of the superna-
tant. This treatment is known to release the IL-1b from
the cells into the supernatant [19]. For the remaining
cells in the 96-well plates, protein assays (Bio-RAD Dc
Protein Assay) were performed as described in the man-
ual. The concentrations of the cytokines and growth fac-
tor were calculated in pg/mg protein.
Western blot
Microglial cells in six-well plates were incubated and sti-
mulated as described above. Cells were washed with ice
cold PBS and lysed with RIPA-Buffer (150 mM NaCl, 10
mM Tris, 0.1% SDS, 1% Triton-X-100, 1% Deoxycholate,
5 mM EDTA, pH 7.4) with protease inhibitors (Roche,
04693159001). Whole cell lysates were electrophoresed
(SDS/PAGE), transferred to polyacrylamide gels, and
immunoblotted using antibodies directed against argi-
nase 1 (BD Bioscience, 6106708) or tristetraprolin (TTP)
(Santa Cruz, G-20: SC-12565). Afterwards the blots
were stripped (0.2 M NaOH) and blotted against tubulin
(Sigma, T7816) or GAPDH (Santa Cruz, SC-25778).
Samples were scanned and analyzed with the Quantity
One program (Bio-Rad). TTP and arginase 1 expression
was analysed in relation to tubulin- or GAPDH
expression
Statistics
The values presented in the graphs correspond to mean ±
SEM of at least three independent experiments. One-way
ANOVA with a specified post-test was used to assess
differences between groups. Asterisks indicate statistically
significant differences with * p < 0.05, ** p < 0.01 and
*** p < 0.001.
Results
Mitochondrial toxins have no effect on LPS-induced
release of pro-inflammatory cytokines
Mitochondrial toxins like 3-NP and rotenone have been
reported to affect cell viability. To exclude toxic effects
of these mitochondrial inhibitors on our experimental
readouts, we examined the effects of 3-NP and rotenone
on cell viability using a WST-1 assay, which measures
mitochondrial dehydrogenase activity, and an LDH
assay, which measures release of LDH by dead cells. As
expected, rotenone and 3-NP both induce a dose-depen-
dent decrease in mitochondrial dehydrogenase activity
(Fig 1a, b). A significant reduction of mitochondrial
dehydrogenase activity was associated with reduced cell
v i a b i l i t ya sm e a s u r e db yL D Hr e l e a s e( F i g1 c ,d ) .T h e
concentrations of 3-NP (0.3 mM and 1 mM) and rote-
none (0.02 μMa n d0 . 2μM) that we used in further
experiments did not induce toxic effects (Table 1).
LPS is the prototypical inflammatory activator of
microglia in in vitro assays. We investigated whether the
mitochondrial toxins 3-NP and rotenone, both of which
affect the mitochondrial electron transport chain, have
an effect on this LPS-induced inflammatory activation of
microglial cells. Stimulation of primary mouse microglial
cells with 1 μg/ml LPS for 18 h induced production of
the pro-inflammatory cytokines IL-6, TNF-a and IL-1b
(Fig 2). The mitochondrial toxins 3-NP and rotenone had
no significant effect on basal or LPS-stimulated produc-
tion of IL-6, TNF-a or IL-1b (Fig 2). Thus, LPS-induced
inflammatory activation in regard to the production of
IL-6, TNF-a or IL-1b seems not to be dependent on the
integrity of the mitochondrial electron transport chain.
Cultures of primary mouse microglial cells typically
contain small amounts of other types of cells, such as
astrocytes [20]. We sought to determine the purity of
our primary mouse microglial cells that were cultured
for 24 h after plating. Using an antibody against CD11b,
a protein specific to macrophages and microglia, we
determined that 90.3 ± 4.9% of the cells in the cultures
were microglia (Fig. 3). An antibody against the
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(Fig. 3). Therefore, the cultures used in this study were
highly enriched in microglial cells.
Mitochondrial toxins inhibit IL-4-induced arginase activity
IL-4 induces an alternative activation of macrophages
and microglia that is characterized by an increase in
arginase activity and expression. This IL-4-induced
alternative activation is anti-inflammatory and is
involved in wound healing and attenuation of inflamma-
tion. To investigate whether mitochondrial toxins have
an effect on this anti-inflammatory activation, we incu-
bated primary mouse microglial cells with 10 ng/ml IL-
4, with or without the mitochondrial toxins rotenone or
3-NP. IL-4 treatment increased arginase activity and
expression (Fig 4). This increase in arginase activity and
expression was reduced by 3-NP and rotenone (Fig 4).
Thus, IL-4-induced alternative activation might be
dependent on a functional mitochondrial electron trans-
port chain.
Mitochondrial toxins inhibit the IL-4-induced reduction in
production of pro-inflammatory cytokines
IL-4-induced, alternatively activated macrophages are
known to counteract the production of pro-inflammtory
cytokines [21]. We investigated whether mitochondrial
toxins changed these IL-4-induced anti-inflammatory
effects.
Figure 1 Mitochondrial toxins induce dose-dependent cell death of microglial cells. Microglial cells were treated with rotenone or 3-NP.
After 24 hrs, cell viability (WST-1) and cell death (LDH) were measured as described in the Methods. Values are mean ± SEM for independent
measurements. n = 8-18 wells (i.e., 4-9 separate experiments performed in duplicate); * = p < 0.05, *** = p < 0.001, significantly different from
untreated cells (ANOVA followed by Dunnett’s Multiple Comparison test).
Table 1 Rotenone and 3-NP do not affect cell viability
WST-1 (% of basal)
Condition Control LPS IL-4 LPS + IL-4
Control 100 174 ± 24 121 ± 19 156 ± 24
0.3 mM 3-NP 96 ± 24 158 ± 23 89 ± 24 132 ± 29
1 mM 3-NP 76 ± 25 141 ± 42 107 ± 31 115 ± 29
0.02 μM Rotenone 146 ± 12 194 ± 42 118 ± 21 132 ± 26
0.2 μM Rotenone 115 ± 21 115 ± 38 114 ± 33 111 ± 27
Microglial cells were treated with rotenone or 3-NP and stimulated with 10
ng/ml IL-4. After 24 hrs, 1 μg/ml LPS was added for 18 hrs. The WST-1 assay
was performed as described in Methods. Values are mean ± SEM for
independent toxicity measurements. n = 6 wells (i.e., 3 separate experiments
performed in duplicate); not significantly different from control (ANOVA
followed by Dunnett’s Multiple Comparison test).
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lated IL-6 and TNF-a secretion (Fig 5a, b, d, e). The
mitochondrial toxins 3-NP and rotenone inhibited this
IL-4-induced reduction of IL-6 and TNF-a release (Fig
5a, b, d, e). IL-4-stimulated microglial cells also reduced
LPS-stimulated IL-1b production (Fig 5c, f), but 3-NP
and rotenone did not have an effect on this IL-4-induced
r e d u c t i o ni nI L - 1 b (Fig 5c, f). This suggests that some
responses associated with alternative activation, such as
counteraction of the production of IL-6 and TNF-a,
depend on fully functional mitochondrial respiration.
Mitochondrial toxins inhibit IL-4-induced IGF-1 release
IL-4-induced, alternatively activated microglia are
known to produce and secrete the neuroprotective insu-
lin-like growth factor-1 (IGF-1) [22,23]. We investigated
if this neuroprotective effect of alternative activation is
also dependent on the mitochondrial electron transport
chain. Microglial cells treated with IL-4 increased IGF-1
release (Fig 6). 3-NP did not have an effect on the IL-4-
induced increase in IGF-1 release at 0.3 mM, but
attenuated this Il-4-induced response at 1 mM. Rote-
none attenuated the IL-4-induced increase in IGF-1
release at all investigated doses, and had a significant
inhibitory effect on basal, non-IL-4-induced IGF-1
release at 0.2 μM (Fig 6). Again, the neuroprotective
effect associated with IL-4-induced production of IGF-1
is dependent on a functional electron transport chain.
Mitochondrial toxins inhibit IL-4-induced tristetraprolin
expression
One mechanism by which IL-4 inhibits the release of
pro-inflammatory cytokines is through increased expres-
sion of tristetraprolin (TTP) via a mechanism mediated
by the transcription factor STAT6 [24]. TTP is an RNA-
binding protein that promotes decay of AU-rich element
(ARE)-containing mRNA, like TNF-a. We investigated
the effect of the mitochondrial toxin rotenone on IL-4-
induced expression of TTP. The mitochondrial toxin
rotenone inhibited IL-4-induced TTP expression (Fig.
7). Thus a functional change in electron transport chain
has an influence on IL-4-induced expression of TTP.
Figure 2 Mitochondrial toxins do not change LPS-stimulated cytokine production. Microglial cells were treated with rotenone or 3-NP.
After 24 hrs, 1 μg/ml LPS was added for 18 hrs. IL-6 (a, d), TNF-a (b, e) and IL-1 b (c, f) were measured as described in Methods. Values are
mean ± SEM for independent cytokine measurements. n = 6-16 wells (i.e., 3-8 separate experiments performed in duplicate); *= p < 0.05,
**= p < 0.001, ***= p < 0.001, significantly different from corresponding basal (ANOVA followed by Bonferroni’s Multiple Comparison test).
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In this study we show that mitochondrial dysfunction in
mouse microglial cells inhibits specific responses of
alternative activation, whereas classic activation
remained unchanged. Evidence that mitochondrial dys-
function inhibits alternative activation is: first, that the
mitochondrial toxins 3-NP and rotenone inhibited IL-4-
induced arginase activity and expression. The second
line of evidence is that these toxins also inhibited IL-4-
induced counteraction of the production of the pro-
inflammatory cytokines IL-6 and TNF-a,l i k e l yb yi n h i -
biting IL-4-induced expression of TTP, an RNA-binding
protein that promotes decay of AU-rich mRNA.
Furthermore, mitochondrial toxins also inhibited IL-4-
induced production of the neurotrophic growth factor
IGF-1. However mitochondrial dysfunction seemed not
to inhibit every aspect of the IL-4 response, as the
mitochondrial toxins did not inhibit IL-4-induced coun-
teraction of the production of IL-1b.W ec o n c l u d e ,
therefore, that some, but not all, of the responses asso-
ciated with the alternative activation status of microglia
are dependent on a functional mitochondrial electron
transport chain. In addition we found that classic activa-
tion of microglia, which was induced by stimulation
with LPS, is not affected by mitochondrial toxins, sug-
gesting that the classic activation might be independent
of the mitochondrial function.
In support of our data are findings in peripheral
macrophages, where alternative activation is dependent
upon functional mitochondria. Inhibition of mitochon-
drial respiration in macrophages inhibits induction of
arginase activity, a hallmark of anti-inflammatory
alternative activation [25]. Furthermore inhibition of
mitochondrial respiration in macrophages abolishes the
Figure 3 Immunocytochemical characterisation of cultures of mouse microglia. Cultures of microglia were immunostained with anti-CD11b
(a) and anti-GFAP (c). Cultures of astrocytes were immunostained with anti-CD11b (c) and anti-GFAP (d). All cells were also counterstained with
DAPI (blue) to identify the cells’ nuclei.
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Page 6 of 10Figure 4 Mitochondrial toxins inhibit IL-4-induced arginase activity. Microglial cells were treated with rotenone or 3-NP and stimulated with
10 ng/ml IL-4 for 24 hrs, and arginase expression was analysed by western blot. A representative blot is shown in (a). Quantification of three
western blots (b). Microglial cells were treated with rotenone or 3-NP and stimulated with 10 ng/ml IL-4 for 32 hrs. Arginase activity was
quantified after 5 h as described in Methods (c). Values are mean ± SEM for independent arginase activity measurements. n = 16-22 wells (i.e., 8-
11 separate experiments performed in duplicate); ***, p < 0.001, significantly different from corresponding basal (ANOVA followed by Bonferroni’s
Multiple Comparison test).
Figure 5 Mitochondrial toxins inhibit the IL-4-induced decrease in LPS-stimulated IL-6 and TNF-a release. Microglial cells were treated
with rotenone or 3-NP and stimulated with 10 ng/ml IL-4. After 24 hrs, 1 μg/ml LPS was added for 18 hrs. IL-6 (a, d), TNF-a (b, e) and IL-1b (c, f)
were measured as described in Methods. Values are mean ± SEM for independent cytokine measurements. n = 6-16 wells (i.e., 3-8 separate
experiments performed in duplicate); *= p < 0.05, **= p < 0.001, ***= p < 0.001, significantly different from corresponding basal (ANOVA
followed by Bonferroni’s Multiple Comparison test).
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tion of IL-6 and TNF-a, whereas this inhibition of mito-
chondrial respiration does not have an effect on the
inflammatory activation of macrophages by LPS [25].
In contrast to Vats et al. [25] we found one IL-4-
induced response that is not affected by the mitochon-
drial toxins used in this study. The IL-4-induced anti-
inflammatory effect on LPS-induced secretion of IL1-b
by microglial cells [26] was not inhibited by mitochon-
drial toxins. Our finding suggests that IL-4-induced
alternative activation is not completely dependent on
mitochondrial respiration. Our findings are in
agreement with the notion that mitochondrial inhibitors
do not alter IL-4-induced STAT-6 signalling, which is
required for the anti-inflammatory response [25]. IL-4
induces the STAT-6-dependent anti-inflammatory
response by up-regulation of the mRNA binding protein
TTP [24]. TTP promotes decay of AU-rich element-
(ARE-) containing mRNA, such as that of TNF-a and
IL-6. Mice lacking TTP develop an inflammatory syn-
drome characterized by arthritis, dermatitis and cachexia
as a consequence of enhanced stability of TNF-a mRNA
and the resulting excess TNF-a production. We have
shown that IL-4 increases LPS-induced TTP expression
Figure 6 Mitochondrial toxins inhibit IL-4-induced IGF-1 release. Microglial cells were treated with rotenone or 3-NP and stimulated with 10
ng/ml IL-4. After 24 hrs, IGF-1 was measured as described in Methods. Values are mean ± SEM for independent IGF-1 measurements. n = 14-16
wells (i.e., 7-8 separate experiments performed in duplicate); *= p < 0.05, **= p < 0.001, ***= p < 0.001, significantly different from corresponding
basal (ANOVA followed by Bonferroni’s Multiple Comparison test).
Figure 7 Mitochondrial toxins inhibit IL-4-induced expression of TTP. Microglial cells were treated with rotenone and stimulated with 10
ng/ml IL-4. After 4 hrs, 1 μg/ml LPS was added for 18 hrs and TTP expression was analysed by western blot. A representative blot is shown in
(a). Quantification of western blots (b). Values are mean ± SEM for three to seven independent western blots.
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ins. This represents a possible molecular mechanism for
the toxin-induced decrease in IL-4-mediated inhibition
of release of TNF-a and IL-6.
Microglial cells treated with rotenone produce super-
oxide, which leads to significant dopaminergic neuronal
cell death [27-29]. It is therefore possible that oxidative
stress is involved in mitochondrial toxin-induced inhibi-
tion of IL-4-mediated anti-inflammatory effects. TTP
phosphorylation and cellular location are influenced by
oxidative stress [30]. Interestingly, treatment of cells
with the mitochondrial uncoupler FCCP (carbonyl cya-
nide p-trifluoromethoxyphenyl-hydrazone) induces co-
localization of TTP with stress granules, whereas
arsenite-induced oxidative stress induces assembly of
phospho-TTP:14-3-3 complexes. Both effects are likely
associated with inhibition of TTP-promoted decay of
mRNA. However, inhibition of TTP may also have an
indirect inhibitory effect on inflammatory responses, as
HIF-a mRNA and the NF-B pathway have been shown
to be regulated by TTP [31,32].
In contrast to Klintworth et al. [33] and our study,
studies by Zhou and colleagues [34] reported a stimula-
tory effect of rotenone on basal secretion of pro-inflam-
matory cytokines by primary rat microglia. This
discrepancy could be due either to species differences or
to an effect of different culture conditions.
Mitochondrial dysfunction in microglial cells have
been observed in several animal models of neurodegen-
eration and aging. In the 3-NP-induced neuronal degen-
eration model in rats, most mitochondrial dysfunctional
signals are associated with activated microglial cells [16].
In aged mice, mitochondrial DNA damage is most pro-
nounced in microglial cells, especially compared to neu-
rons [15]. Hayashi et al. [15] discuss the extremely slow
mitochondrial turnover in microglia and the idea that
abundant damaged mitochondria may therefore accu-
mulate in microglia. In line with this is the finding that
microglial cells in brain are self-maintaining cells that
are normally not renewed by bone marrow-derived pro-
genitor cells [35,36], and are therefore prone to an accu-
mulation of mitochondrial damage. Further research is
necessary to determine whether mitochondrial dysfunc-
tion occurs in microglial cells in other neurological
diseases.
Conclusions
In summary, we have shown that mitochondrial dys-
function in mouse microglial cells inhibit some aspects
of alternative activation, whereas classic activation seems
to remain unchanged. If, in neurological diseases, micro-
glial cells are also affected by mitochondrial dysfunction,
they might not be able to induce a full anti-inflamma-
tory alternative response and thereby exacerbate
neuroinflammation. This would be associated with detri-
mental effects for the CNS since wound healing and
attenuation of inflammation would be impaired. Recon-
stituting the alternative microglial response might there-
fore be a novel strategy to halt disease progression.
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